2022 Access to Medicine Index reveals improvement

The article acknowledges, however, that despite the pharma industry's rapid response to address COVID-19, there is little evidence of research and development efforts for other emerging diseases, which disproportionately affect those living in low- and middle-income countries.

James Hazel, Research Programme Manager for the Index, is quoted: "Companies must consider the depths of their plans, strength of their supply chains, and equity of their pricing strategies to reach the most vulnerable populations."

Read the article on the GOLD website.